FG-2216 is a potent, orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2), a class of compounds investigated for its role in stabilizing hypoxia-inducible transcription factors… Read more
FG-2216 is a potent, orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2), a class of compounds investigated for its role in stabilizing hypoxia-inducible transcription factors and treating conditions such as anemia associated with chronic kidney disease. Pharmaceutical laboratories utilize high-quality reference standards of FG-2216 and its derivatives to support rigorous analytical testing, ensuring the precision of drug development protocols. The associated impurities and metabolic intermediates are essential for comprehensive impurity profiling and the accurate identification of degradation products during stability studies. Additionally, stable isotope labelled compounds in this category serve as critical internal standards for quantitative analysis, enabling precise measurement in pharmacokinetic studies and validation of liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods. These analytical tools are vital for researchers engaged in quality control and the development of reliable assays for this therapeutic class.